NEW YORK (GenomeWeb News) – SQI Diagnostics reported after the close of the market on Tuesday that it had no revenues for its fiscal third quarter, compared to C$9,000 (US$9,064) from the year-ago period.

In documents filed with SEDAR, the Canadian financial information filing system, Toronto-based SQI said that the revenue drop resulted from one customer, Gamma Dynacare Medical Labs, choosing not to purchase QuantiSpot RA test kits in the quarter. Subsequent to the end of the third quarter, GDML reordered the kits.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.